

## ASX Announcement (ASX: HLS)

ASX Limited  
Market Announcements Office  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

30 September 2025



ACN 064 530 516  
REGISTERED OFFICE:  
LEVEL 22  
161 Castlereagh Street  
SYDNEY NSW 2000  
TEL: +61 2 9432 9400  
FAX: +61 2 9432 9447

### Board Changes

Healius Limited ("**Healius**") (ASX: HLS) announces the resignations of Dr Michael Stanford and Mr Neil Vinson as Non-Executive Directors effective today, 30 September 2025 and the appointment of two new Non-Executive Directors - Mr Steven Rubic effective 1 December 2025 and Mr Chris Hall effective today, 30 September 2025.

Mr Rubic will bring to the Board 25 years of executive leadership in healthcare. He has held CEO positions at St Vincent's and Mater Health Sydney, I-MED Radiology Network and Healthscope. He is also an experienced Non-Executive Director. Mr Rubic is currently a Non-Executive Director of the Mater Hospitals Group, Pacific Smiles Group Limited (ASX:PSQ) and Catholic Healthcare Limited. He is also Deputy Chair of TPG private equity owned InvoCare.

Mr Rubic holds a Master of Business Administration (MGSM) and a Bachelor of Health Administration (UNSW). He is a Fellow of both the Australian Institute of Company Directors and the Australasian College of Health Service Management.

Mr Hall was nominated for appointment to the Board by Tanarra Capital, whose interest in Healius increased from 11.97% to 19.81% on 26 August 2025. The nomination by Tanarra Capital followed Mr Neil Vinson's resignation from his role as an Investment Manager of Tanarra Capital.

Mr Hall brings to the Board extensive experience across asset management, superannuation and, recently, biotechnology. His career has included roles as Chair, Non-Executive Director and Chief Investment Officer, along with senior executive positions in Australia and Hong Kong.

Mr Hall's current roles include Chair of BiomeBank, Non-Executive Director, Investment Committee Member and Audit Committee Member of AMP Superannuation, Non-Executive Director and Audit Committee Member of Funds SA, Investment Committee Chair of Perks Private Wealth, and Member of the Advisory Board to the Long-Term Value Fund at Tanarra Capital.

Mr Hall holds a Bachelor of Business from the University of South Australia and he has completed the Professional Management Program (MBA Program) at the University of Adelaide. He is also a member of the Australian Institute of Company Directors.

Dr Stanford was appointed to the Board as a Non-Executive Director in September 2023. He has served as a member of the Board's Audit Committee from September 2023 and as Chair of the Board's Risk Management Committee since September 2024. He was also a member of the People, Governance and Remuneration Committee from October 2023 to August 2024.

Mr Vinson was appointed to the Board as a Non-Executive Director in March 2025.

Kate McKenzie, Healius Chair, said: "The Board is delighted Steven and Chris are joining the Board. Their appointments ensure an ongoing appropriate range of diversity, skills and expertise within the Board to oversee the delivery of Healius' T27 strategy. At the same time as welcoming Steven and Chris, the Board also wishes to thank Michael and Neil for their valued contributions as Directors of Healius."

**ENDS**

The release of this announcement has been authorised by the Chair of Healius.

For further information contact:

**Kate McKenzie**

Chair

Healius Limited

+61 (0) 466 023 858

[investor.relations@healius.com.au](mailto:investor.relations@healius.com.au)